Humacyte (NASDAQ:HUMA - Get Free Report)'s stock had its "buy" rating reaffirmed by stock analysts at TD Cowen in a report issued on Friday, Benzinga reports. They presently have a $10.00 price objective on the stock. TD Cowen's price target indicates a potential upside of 98.81% from the stock's previous close.
HUMA has been the topic of a number of other research reports. Cantor Fitzgerald reissued an "overweight" rating and issued a $13.00 price objective on shares of Humacyte in a research note on Friday, September 20th. EF Hutton Acquisition Co. I raised shares of Humacyte to a "strong-buy" rating in a research note on Monday, September 9th. Benchmark restated a "buy" rating and issued a $15.00 price target on shares of Humacyte in a research report on Thursday, October 10th. Finally, BTIG Research reiterated a "buy" rating and set a $10.00 price objective on shares of Humacyte in a research report on Friday. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $10.00.
Check Out Our Latest Research Report on Humacyte
Humacyte Price Performance
HUMA traded up $0.17 on Friday, reaching $5.03. The company had a trading volume of 5,846,303 shares, compared to its average volume of 2,319,289. Humacyte has a one year low of $1.96 and a one year high of $9.97. The company has a market capitalization of $598.99 million, a P/E ratio of -5.03 and a beta of 1.45. The company has a fifty day moving average of $5.78 and a 200-day moving average of $5.89. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.61.
Humacyte (NASDAQ:HUMA - Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). As a group, equities research analysts anticipate that Humacyte will post -1.09 earnings per share for the current year.
Insiders Place Their Bets
In related news, Director Brady W. Dougan sold 352,112 shares of the stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $6.35, for a total value of $2,235,911.20. Following the completion of the sale, the director now directly owns 3,677,262 shares of the company's stock, valued at approximately $23,350,613.70. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Humacyte news, CEO Laura E. Niklason sold 277,090 shares of Humacyte stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $6.47, for a total transaction of $1,792,772.30. Following the completion of the sale, the chief executive officer now owns 4,029,374 shares of the company's stock, valued at $26,070,049.78. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Brady W. Dougan sold 352,112 shares of the business's stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $6.35, for a total transaction of $2,235,911.20. Following the transaction, the director now owns 3,677,262 shares in the company, valued at approximately $23,350,613.70. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,084,153 shares of company stock worth $6,869,996. Corporate insiders own 23.10% of the company's stock.
Institutional Trading of Humacyte
A number of institutional investors have recently bought and sold shares of the company. nVerses Capital LLC purchased a new stake in shares of Humacyte during the 2nd quarter worth about $28,000. Principal Financial Group Inc. bought a new position in Humacyte during the second quarter valued at approximately $83,000. Profund Advisors LLC acquired a new stake in Humacyte in the second quarter valued at approximately $97,000. Hartline Investment Corp acquired a new stake in Humacyte in the first quarter valued at approximately $70,000. Finally, XTX Topco Ltd bought a new stake in Humacyte in the second quarter worth approximately $110,000. Institutional investors and hedge funds own 44.71% of the company's stock.
Humacyte Company Profile
(
Get Free Report)
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
See Also
Before you consider Humacyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humacyte wasn't on the list.
While Humacyte currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
